HIGH-DOSE BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN PRIOR TO TRANSPLANTATION

被引：0
|
作者：
MARIT, G
CONY, P
DAVID, B
BROUSTET, A
REIFFERS, J
机构：
来源：
BONE MARROW TRANSPLANTATION | 1988年 / 3卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [31] High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
    D Sivaraj
    W Bacon
    G D Long
    D A Rizzieri
    M E Horwitz
    K M Sullivan
    Y Kang
    Z Li
    N J Chao
    C Gasparetto
    Bone Marrow Transplantation, 2018, 53 : 34 - 38
  • [32] Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation
    R Kobayashi
    N Watanabe
    A Iguchi
    Y Cho
    M Yoshida
    H Arioka
    H Naito
    T Shikano
    Y Ishikawa
    Bone Marrow Transplantation, 1998, 21 : 217 - 220
  • [33] High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Sivaraj, D.
    Bacon, W.
    Long, G. D.
    Rizzieri, D. A.
    Horwitz, M. E.
    Sullivan, K. M.
    Kang, Y.
    Li, Z.
    Chao, N. J.
    Gasparetto, C.
    BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 34 - 38
  • [34] Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation
    Kobayashi, R
    Watanabe, N
    Iguchi, A
    Cho, Y
    Yoshida, M
    Arioka, H
    Naito, H
    Shikano, T
    Ishikawa, Y
    BONE MARROW TRANSPLANTATION, 1998, 21 (03) : 217 - 220
  • [35] Feasibility of high-dose paclitaxel in the conditioning regimen for autologous haematopoietic transplantation
    Perez-Calvo, J
    Fernandez-Hidalgo, O
    Aramendia, JM
    Salgado, E
    Lopez-Picazo, JM
    Rebollo, J
    Rifon, J
    Prosper, F
    Rocha, E
    Martin-Algarra, S
    BONE MARROW TRANSPLANTATION, 2004, 33 : S39 - S40
  • [36] Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
    Anagnostopoulos, A
    Aleman, A
    Ayers, G
    Donato, M
    Champlin, R
    Weber, D
    Alexanian, R
    Giralt, S
    CANCER, 2004, 100 (12) : 2607 - 2612
  • [37] Busulfan / Melphalan / Bortezomib (Bu-Mel-Vet) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Zhong, Xiaobo
    Sterrenberg, Danielle
    Vesole, David H.
    BLOOD, 2013, 122 (21)
  • [38] BUSULFAN PLUS CYCLOPHOSPHAMIDE AND ETOPOSIDE VERSUS HIGH-DOSE MELPHALAN AS CONDITIONING IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
    Park, Seonyang
    Lee, Youngjoon
    Lim, Sungnam
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 484 - 484
  • [39] Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant
    Puckrin, Robert
    Chua, Neil
    Shafey, Mona
    Stewart, Douglas A.
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2444 - 2452
  • [40] High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma
    谷景立
    China Medical Abstracts(Internal Medicine), 2019, 36 (04) : 230 - 231
12345